Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide therapy for scleroderma

A Akesson1

  • 1Department of Rheumatology, Lund University Hospital, Sweden.

Current Opinion in Rheumatology
|November 13, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accuracy of transvaginal ultrasound versus MRI in the PreOperative Diagnostics of low-grade Endometrial Cancer (PODEC) study: a prospective multicentre study.

Clinical radiology·2022
Same author

Associations of PFAS-related plasma metabolites with cholesterol and triglyceride concentrations.

Environmental research·2022
Same author

The alarmins high mobility group box protein 1 and S100A8/A9 display different inflammatory profiles after acute knee injury.

Osteoarthritis and cartilage·2022
Same author

Impact of lymphadenectomy and lymphoedema on health-related quality of life 1 year after surgery for endometrial cancer. A prospective longitudinal multicentre study.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Incidence of distal radius fracture in a general population in southern Sweden in 2016 compared with 2001.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Cardiovascular and cancer mortality in relation to dietary polychlorinated biphenyls and marine polyunsaturated fatty acids: a nutritional-toxicological aspect of fish consumption.

Journal of internal medicine·2019
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Scleroderma lung disease is a major cause of death. Cyclophosphamide shows promise for treating interstitial lung disease and pulmonary hypertension in scleroderma patients, pending further placebo-controlled trials.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Immunology

Background:

  • Pulmonary complications are the leading cause of mortality in systemic sclerosis.
  • Interstitial lung disease (ILD) and pulmonary hypertension (PH) are significant contributors to poor outcomes.
  • Effective therapeutic strategies for scleroderma-related lung disease remain a critical unmet need.

Purpose of the Study:

  • To review the current understanding of pulmonary manifestations in scleroderma.
  • To highlight the importance of treating ILD and PH in scleroderma patients.
  • To discuss the potential role of cyclophosphamide in managing scleroderma lung disease.

Main Methods:

  • Literature review of studies on scleroderma and its pulmonary complications.
  • Analysis of treatment options for interstitial lung disease and pulmonary hypertension.

Related Experiment Videos

  • Evaluation of existing evidence for cyclophosphamide in scleroderma lung disease.

    • Main Results:

    • Pulmonary disease is the primary cause of death in scleroderma.
    • Early and effective treatment of ILD and PH is crucial.
    • Cyclophosphamide may offer a therapeutic benefit for scleroderma lung disease.

    Conclusions:

    • Scleroderma lung disease requires prompt and aggressive management.
    • Cyclophosphamide represents a potential treatment option for patients with scleroderma-related interstitial lung disease and pulmonary hypertension.
    • Further placebo-controlled studies are warranted to definitively establish the efficacy of cyclophosphamide.